Design-Elememt

vfa Press Release 003/2014

"Trial and error” at the patients’ expense


"Trial and error” at the patients’ expense
(© vfa / H. Klappert)
The German Bundestag is implementing a number of pharmaceutical policy changes within the scope of the 14th law amending Book V of the German Social Code.
read on

AMNOG

Early benefit assessment: Reviews and negotiations – Problems and conflicts


Early benefit assessment: Reviews and negotiations – Problems and conflicts
(© vfa / Golden Section Graphics - Dirk Aschoff)
When the legislature created the Act on the Restructuring of the Pharmaceutical Market (AMNOG), it has established a process that is as complex as it is complicated, and in some places it is questionable from a methodological standpoint. To facilitate an easier categorization of individual aspects of the procedure, we have developed an interactive information graphic in cooperation with ÄrzteZeitung that illustrates the process of the early benefit assessment, including the parties involved and the resulting problems and conflicts.
read on

Country Report Germany – February 2012

General political situation


In contrast to most other European countries, Germany’s economy performed very well in 2011. As a result, the social security funds – especially the health fund – are well funded and show surpluses. Due to the uncertainties induced by the European...
read on

In the Spotlight: Pharmaceutical expenditures


In the Spotlight: Pharmaceutical expenditures
(© vfa)
Ways to achieve health care savings are currently being discussed. Governmental policy and the health insurancers plan to create these savings primarily by way of prescription drugs. Legislative decisions should be based on facts. Here are some facts regarding prices and spending on medicines in Germany.
read on

Vaccine research and production: Europe is in the lead


Vaccine research and production: Europe is in the lead
(© GlaxoSmithKline)
Europe is in the lead when it comes to vaccines: This area covers two-thirds of industrial research and development activities, 60 percent of the employees and even 90 percent of worldwide production. A total of 84 percent of the European production is exported, half of it for humanitarian projects in developing countries.
read on
The Pharmaceutical Industry in Germany

Germany: The Perfect Location for Research, Production and Sales - a publication by GERMANY TRADE & INVEST and vfa
Brochure Download